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1. Introduction 
Recrystallization can be described simply as a process whereby a crystalline form of a 
compound may be obtained from other solid-state forms, being themselves crystalline or 
amorphous, of the same substance. Recrystallization is the process most often employed for 
the intermediate separation and last-step purification of solid active pharmaceutical 
ingredients (APIs) (Shekunov & York, 2000; Tiwary, 2006). Chemical purity is however not 
the only property of a pharmaceutical active that will affect its performance. Crystal 
structure (Table 1), crystal habit (Table 2) and particle size all play a part. Polymorphism 
(different crystal structures of the same substance) affects the physico-chemical properties 
and stability of an API, whereas crystal habit and particle size mostly affect various indices 
impacting on dosage form production and performance: particle orientation; flowability; 
packing and density; surface area; aggregation; compaction; suspension stability; and 
dissolution (Blagden et al., 2007; Doherty & York, 1988; Tiwary, 2006). 
 
 
System 
Relationship between 
lattice parameters 
Cubic 
a = b = c 
α = β = γ = 90° 
Tetragonal 
a = b ≠ c 
α = β = γ = 90° 
Orthorhombic 
a ≠ b ≠ c 
α = β = γ = 90° 
Rhombohedral 
(or trigonal) 
a ≠ b ≠ c 
α = β = γ ≠ 90° 
Hexagonal 
a = b ≠ c 
α = β = 90°, γ = 120° 
Monoclinic 
a ≠ b ≠ c 
α = γ = 90°, β ≠ 90° 
Triclinic 
a ≠ b ≠ c 
α ≠ β ≠ γ ≠ 90° 
Table 1. Crystal systems and lattice parameters. (Adapted, with permission of Informa 
Healthcare, from Rodríguez-Homedo et al., 2006.) 
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Crystal morphology Description 
Acicular Slender, needle-like crystal 
Aggregate Mass of adhered crystals 
Blade Long, thin, flat crystal 
Dendritic Tiny crystallites forming a tree-like pattern 
Equant/cubic Crystal with similar length, width and thickness 
Fiber Long, thin needle; longer than acicular 
Flake/lath Thin, flat crystal similar in width and length 
Plate/platy Flat crystals with similar width and length but thicker than a flake 
Prismatic/bipyramid
Hexagonal crystals with faces parallel to the growth axis; width and 
thickness greater than acicular and shorter in length 
Rod Cylindrical crystals elongated along one axis 
Rosette/spherulite Sphere composed of needles or rods radiating from a common center 
Tablet/tabular Flat crystal with similar width and length but thicker than a plate 
Table 2. Descriptions of common pharmaceutical crystal morphologies. (Adapted, with 
permission of Informa Healthcare, from Rodríguez-Homedo et al., 2006.) 
 
Fig. 1. Diagram showing the phenomena that govern solid-state transformations. 
Mechanical, thermal and chemical (solvents, additives, impurities, relative humidity) 
stresses affect the competition (or reinforcement) among these processes. (Adapted, with 
permission of Informa Healthcare, from Rodríguez-Homedo et al., 2006.) 
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The number of solid-state forms that an API could exist in relies on the range of non-
covalent interactions and molecular assemblies, the order range, and the balance between 
entropy and enthalpy that defines the free energy states and processes (Figure 1). When an 
API exists as more than one solid-state form, thermodynamics control their relative stability 
and the conditions and direction in which a transformation can occur, whilst kinetics 
determine how long it will take for a transformation to reach equilibrium. Thermodynamics 
establish the stability domains of the solid-states, but once a metastable domain is 
encountered, the kinetic pathways will determine which form will be created and for how 
long it will survive (Rodríguez-Spong et al., 2004). 
Small changes in recrystallization procedure can influence the crystallization process and 
may lead to changes in API crystal structure, crystal habit and particle size with subsequent 
variability of raw material characteristics and dosage form performance. Herein lies the 
challenge and the opportunity: manufacturers of pharmaceutical actives go to great lengths 
to ensure production uniformity, but a pharmaceutical researcher might choose to alter 
recrystallization conditions to manipulate API characteristics. 
Crystallization is generally thought of as the evolution from solution or melt of the 
crystalline state (Blagden et al., 2007), but a broader definition includes precipitation and 
solid-state transitions (Shekunov & York, 2000). Crystallization methods can be solvent or 
non-solvent based and the varied reaction conditions generate different crystal forms (Banga 
et al., 2004). Non-solvent based methods include sublimation, thermal treatment, 
desolvation of solvates, grinding and crystallization of a melt (Guillory, 1999). Applied in 
polymorph screening studies, traditional crystallization approaches most often will not 
yield all possible polymorphs of a given API. Therefore, there is a continuous search for 
innovative methods of manipulating the crystallization process (Rouhi, 2003). 
2. Solvent based recrystallization 
In solution, crystallization is the creation of a crystalline phase by a process (Figure 2) 
initiated by molecular aggregation, leading to the formation of nuclei (the smallest possible 
units with defined crystal lattice) and ultimately crystal growth (Banga et al., 2004). 
2.1 Parameters that influence nucleation and crystal growth 
The sections that follow will address factors that influence solvent recrystallization in 
general and will not venture into the specifics of specialized solvent-based production 
methods like spray-drying, freeze-drying, etc. The reader should keep in mind that although 
different parameters are discussed under separate headings, they are interactive and not 
independent of each other. For example: changing the composition of a solvent system will 
change the level of saturation; changes in temperature alter viscosity and level of saturation; 
agitation may increase temperature; etc. 
Each of the parameters discussed can influence polymorphism, and polymorphism in turn 
affects crystal habit. It is also well-known that each polymorph of an API can exhibit 
multiple crystal habits, therefore a parameter might influence crystal habit without 
changing the internal structure of the crystals produced (Tiwary, 2006). 
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Fig. 2. The course of crystallization and its rate-limiting steps. (Adapted, with permission of 
Touch Briefings, from Banga et al., 2004.) 
2.1.1 Concentration and temperature 
The difference in chemical potential between the crystallization solution and the solid phase 
is the fundamental driving force for crystallization, but it is more convenient to express the 
driving force in terms of supersaturation (Fujiwara et al., 2005). Supersaturation (the 
difference between solution concentration and saturation concentration at a specific 
temperature) leads to the creation of metastable (far from equilibrium) liquid states and 
crystallization provides a means to reduce the free energy of the system to the most stable 
state (equilibrium) (Rodríguez-Homedo et al., 2006). The kinetics of nucleation and crystal 
growth are strongly dependent on supersaturation (Braatz, 2002; Togkalidou et al., 2002). An 
increase in the degree of supersaturation of a solution leads to a reduction in the size of 
crystals produced. At high supersaturation nucleation is more rapid than growth, resulting 
in the precipitation of fine particles (Carstensen et al., 1993; Tiwary, 2006). It is therefore 
important to control the degree of supersaturation during crystallization, because the size, 
shape and solid-state form of the crystals produced are all influenced by supersaturation 
(Fujiwara et al., 2005). 
Supersaturation is typically achieved through processes that either increase the solute 
concentration (evaporation or dissolution of a metastable solid phase with subsequent 
transformation to the more stable, but less soluble form) or decrease the solubility of the 
solute (cooling, addition of an antisolvent, pH change or the addition of ions that participate 
in precipitation of the solute) or through a combination of these strategies (Fujiwara et al., 
2005; Rodríguez-Homedo et al., 2006).  
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The main effect of temperature on crystallization from solution is secondary to its influence 
on the solubility of the solute, and subsequently the degree of saturation of the solution. 
Although molecular recognition is required for the formation of molecular clusters, and this 
is dependent on molecular mobility and collision rates, both of which increase at higher 
temperatures, the molecular mobility in liquids is too high to be the rate-limiting factor in 
nucleation and crystal growth (Rodríguez-Spong et al., 2004).  
The relationship between nucleation rate and supersaturation is well known and Figure 3 
illustrates that the number of nuclei generated by a high rate of cooling increases 
exponentially with increasing supersaturation. A high number of nuclei at the outset limits 
their growth potential (Tung et al., 2009).  
In cases where the crystallization of a metastable polymorph precedes in-solvent 
transformation to a more stable polymorph as described by Ostwald’s Rule of Stages 
(Boistelle & Astier, 1988; Ostwald, 1897), the solvent-mediated transformation can be 
affected by the temperature of the crystallization medium (Stieger et al., 2009), because the 
process is thermally activated (Beckman, 2000).  
Temperature cycling or oscillation is sometimes used to accelerate the effect of post-
crystallization Ostwald Ripening in slurries containing just one polymorph of an API. Small 
particles and rough edges of larger particles dissolve faster during heating periods, followed 
by their recrystallization onto the existing crystals during cooling. The overall effect is more 
uniformly shaped particles and a narrower particle size distribution range (Kim et al., 2003; 
Mullin, 2001). 
 
Fig. 3. Nucleation versus supersaturation (Adapted, with permission of John Wiley and 
Sons, from Tung et al., 2009). 
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2.1.2 Interfaces and surfaces 
Nucleation can be either homogeneous or surface catalyzed (Figure 4). Homogeneous 
nucleation seldom occurs in volumes greater than 100 μl, because solutions contain random 
impurities that may induce nucleation. Surface catalyzed nucleation can be promoted by 
surfaces of the crystallizing solute (secondary nucleation) or a surface/interface of different 
composition than the solute may induce nucleation (heterogeneous nucleation) by 
decreasing the energy barrier for the formation of nuclei (Rodríguez-Homedo et al., 2006). 
 
Fig. 4. Mechanisms for crystal nucleation. (Adapted, with permission of Informa Healthcare, 
from Rodríguez-Homedo et al., 2006.) 
Surfaces promoting heterogeneous nucleation may be introduced into the crystallization 
solution intentionally (as a means of controlling crystal form of the product) (Rodríguez-
Spong et al., 2004) or unintentionally (dust and other impurities), or they may be an 
unavoidable part of the process (crystallization vessel, vessel-solution interface and the 
solution-air interface) (Florence & Attwood, 2006; Kuzmenko et al., 2001). 
The intentional introduction, into crystallization solutions, of surfaces that catalyze 
nucleation is known as “seeding”. Usually, seeding is performed by introducing crystals of 
the solute that have the preferred crystal structure one wishes to obtain. Seeding can also be 
performed using isomorphous substances that differ from the solute (Florence & Attwood, 
2006). Seeding techniques can be applied to initiate crystallization; to control particle size – 
usually when larger crystals with uniform size distribution are required; to avoid 
encrustation through spontaneous nucleation; to control polymorphic form; and to obtain 
crystals of high purity, high perfection, desired orientation and sufficient size for crystal 
structure determination by X-ray diffraction (Beckman, 2000). 
When the concentration of an API in the crystallization medium is increased past its 
solubility curve (Figure 5), whether by cooling or by evaporation of solvent, nucleation does 
not immediately occur. The solution has to reach a certain concentration-temperature point 
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where spontaneous nucleation occurs – this is the border of the metastable zone. For seeding 
to be successful in producing just the required product, the concentration and temperature 
of the crystallization medium must be strictly controlled within this zone. If the solubility 
line is crossed to the left, the seed crystals will dissolve and if the metastable zone limit is 
crossed to the right, spontaneous nucleation will take place and could result in unwanted 
crystal forms (Beckman, 2000; Fujiwara et al., 2005). 
 
Fig. 5. The operating region of seeded industrial batch crystallization is the metastable zone, 
which is bound by the solubility curve and the metastable limit for the specific API. The 
concentration-temperature profile (control trajectory) to be used lies within the metastable 
zone (operating region). (Adapted, with permission of Elsevier, from Fujiwara et al., 2005.) 
In evaporative crystallization, crystals are sometimes observed to form preferentially near 
the surface of the solution, due to a higher local concentration of solute. The meniscus of a 
solution can also have geometry favoring higher evaporation rates, with crystals then 
forming at the contact line with the crystallization vessel (Capes & Cameron, 2007). 
2.1.3 Solvent 
Dependent on the conditions employed, the crystallization of API polymorphs from a 
solvent may be under kinetic or thermodynamic control. When crystallization of a 
dimorphic compound (Figure 6) is conducted sufficiently above or below the transition 
point, in an area defined by the solubility curves of the two polymorphs, the solvent used is 
immaterial provided that the API solubility is adequate to allow the prescribed 
concentrations to be reached. Irrespective of the kinetics, the outcome is under total 
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thermodynamic control. If crystallization takes place outside the area described above (B2, 
C1, D1, E1 and E2), the choice of solvent may or may not be critical. This will be determined 
by the relative kinetics of formation, growth, and transformation of the two polymorphs in 
the various solvents (Threlfall, 2000). 
 
Fig. 6. Polymorphic system of two enantiomorphically related polymorphs I and II. 
(Transition point X at TX; A-G, initial state of hot, undersaturated solutions; A1-G1, B2 and 
E2, state of solution at point of initial crystallization. If B is seeded at B1, it behaves as A1.)  
(Adapted, with permission of the American Chemical Society, from Threlfall, 2000.) 
Recrystallization from solvents often leads to the isolation of solvates, in fact, API solvates 
are very common (Griesser, 2006). Although they have a recognized potential to improve 
dissolution kinetics (Brittain & Grant, 1999; Haleblian, 1975; Tros de Ilarduya et al., 1997), 
they are rarely selected for further development or dosage form formulation – the only 
exceptions being hydrates. The main reasons for the rarity of marketed API solvates are 
their solid-state metastability and the relative toxicity of any included solvent (Douillet et al., 
2011). It goes without saying that, in the production of solvates, the solvent/s used for 
recrystallization will be the one/s that could potentially be included in the crystal lattice. 
The nature of the crystallization solvent can affect crystal habit, regardless of change in 
polymorphism (Stieger et al., 2010a). The interaction of the solvent at the different crystal-
solution interfaces may lead to altered roundness of growing crystal faces and/or edges, 
changes in crystal growth kinetics, and enhancement or inhibition of crystal growth at 
certain faces (Figure 7), thereby changing the crystal habit (Stoica et al., 2004; Tiwary, 2006). 
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Fig. 7. Crystal habits arising from growth inhibition at crystal faces. (Adapted, with 
permission of Informa Healthcare, from Carstensen et al., 1993.) 
2.1.4 Agitation, mixing and stirring 
Mixing of crystallization solutions and crystal slurries is often necessary, especially in 
industry, to ensure homogeneity (heat transfer, dispersion of additives, uniformity of crystal 
suspension, avoidance of settling, etc.). Its effects on nucleation, both primary and 
secondary, and crystal growth are far reaching and complex. An unagitated solution can, in 
general, be cooled further before onset of nucleation, because the overall result of mixing is a 
decrease in the width of the metastable zone. In a mixed solution at constant 
supersaturation, with no crystals yet present, mixing intensity can reduce induction time – 
the time elapsed before crystals first appear. Induction time decreases up to a critical speed 
and then remains unchanged (Karpinski & Wey, 2001; Mullin, 2001; Tung et al., 2009). 
Mixing actively generates secondary nuclei through crystal-crystal, crystal-vessel and 
crystal-impeller impacts. A greater number of nuclei generated in agitated systems leads to 
a decrease in the ultimate crystal size of the product. Mixing also has an intensity dependent 
effect on the mass transfer rate of growing crystals with a growth limiting outcome (Tung et 
al., 2009). 
It has been found that stirring can reproducibly affect the chiral symmetry of crystallization 
products. If a substance crystallizes as an equal mixture of dextro and levo crystals when 
unstirred, its chiral symmetry can be disrupted by stirring (Kondepudi et al., 1990; McBride 
& Carter, 1991). This phenomenon has been attributed to the effect of stirring on secondary 
nucleation (Kondepuddi & Sabanayagam, 1994). 
2.1.5 Pressure 
Almost all polymorph screening studies and industrial crystallization processes are 
performed under ambient pressure, but low pressure is also often applied to increase the 
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rate of solvent evaporation. As with rapid cooling, rapid evaporation leads to higher 
nucleation rates. 
Only recently have researchers turned their attention to high pressure recrystallization from 
solution as an added dimension in the search for new pharmaceutical polymorphs and 
solvates. High pressure encourages denser structures in which molecules must pack more 
efficiently and this means that changes in relative orientations are likely to occur. This gives 
rise to different themes of molecular interactions, the strengths of which are in turn sensitive 
to distance and therefore the effects of pressure. The interactions between solute and solvent 
molecules are also modified by pressure, changing the solubility of a given polymorph or 
solvate. In some instances, the differences in solubility between two forms might also 
change, thereby encouraging recrystallization of one form at the expense of another 
(Fabbiani et al., 2004). 
2.1.6 Moisture and humidity 
When recrystallizing from hygroscopic organic solvents, care should be taken to use only 
properly dried solvents (Table 3) or newly opened containers from reputable suppliers. If a 
crystallization process generates a metastable intermediary form, it can absorb water when 
exposed to moisture and change into a hydrate. Water molecules, because of their small size 
and multidirectional hydrogen bonding capabilities, are particularly suited to fill structural 
voids (Manek & Kolling, 2004). If a crystallization system is open to atmospheric conditions, 
as is likely to be the case with evaporative crystallization, hygroscopic solvents will absorb 
moisture from the air if present. Should an evaporative crystallization process be sensitive to 
the presence of moisture, additional measures will have to be put in place to eliminate 
atmospheric humidity. 
 
Organic Solvent Drying Agent 
Alcohols 
Anhydrous potassium carbonate; anhydrous 
magnesium or calcium sulphate; calcium oxide. 
Alkyl halides 
Aryl halides 
Anhydrous calcium chloride; anhydrous sodium, 
magnesium or calcium sulphate; phosphorous 
pentoxide. 
Saturated and aromatic 
hydrocarbons 
Ethers 
Anhydrous calcium chloride; anhydrous calcium 
sulphate; metallic sodium; phosphorous pentoxide. 
Aldehydes Anhydrous sodium, magnesium or calcium sulphate. 
Ketones 
Anhydrous sodium, magnesium or calcium sulphate; 
anhydrous potassium carbonate. 
Organic bases (amines) 
Solid potassium or sodium hydroxide; calcium oxide; 
barium oxide. 
Organic acids Anhydrous sodium, magnesium or calcium sulphate. 
Halogenated solvents* Calcium hydride; phosphorous pentoxide. 
* Never dry halogenated solvents with alkali metals or alkali metal hydrides as this can cause violent 
explosions. 
Table 3. Common drying agents for organic solvents. (Adapted, with permission of Indian 
Streams Research Journal, from Shinde et al., 2011.) 
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2.1.7 Addition of salts, polymers or antisolvents 
The addition of salts, polymers or antisolvents can be used to create supersaturation of the 
solution by decreasing the solute solubility in the crystallization medium. Ions, polymeric 
molecules, or other substances introduced into the crystallization solvent can also act as 
impurities for growing crystals. These substances may get adsorbed in the crystal lattice of a 
growing crystal and disturb the regular and repeating arrangements of the crystal, creating 
defects and leading to polymorphic modifications. Impurities, and surfactants in particular, 
can also inhibit crystal growth at certain crystal faces, resulting in crystal habit changes 
(Tiwary, 2006). 
When selecting suitable solvents for antisolvent crystallization, one should select a pair that 
is miscible. The solute must be more soluble in one solvent and less soluble in the other 
(antisolvent). A water-soluble API will most likely be more soluble in a polar solvent and 
less soluble in a non-polar solvent (Table 4). The opposite holds true for a poorly water-
soluble API. Antisolvent crystallization is performed by dissolving the API in the solvent 
and then gradually adding an antisolvent. This results in a decrease of solute solubility and 
an increase in supersaturation – much like cooling crystallization (Nonoyama et al., 2006; 
Stieger et al., 2010a; Zhou et al., 2006). Reverse addition is a variation of antisolvent 
recrystallization whereby the API solution is added to the antisolvent. The resulting rapid 
increase in supersaturation leads to swift nucleation and the precipitation of very fine 
particles (Tung et al., 2009). The composition of the crystallization medium can affect both 
the crystal form and crystal habit of the product (Stieger et al., 2010a). 
 
Solvent 1 (more polar) Solvent 2 (less polar) 
Solvent Dielectric constant (ε) Solvent Dielectric constant 
(ε) 
Water 78.3 Ethanol 24.3 
Water 78.3 Acetone 20.7 
Methanol 32.6 Dichloromethane 9.08 
Ethanol 24.3 Acetone 20.7 
Acetone 20.7 Diethyl ether 4.34 
Acetone 20.7 Petroleum ether 1.90 
Diethyl ether 4.34 Hexane 1.89 
Ethyl acetate 6.02 Cyclohexane 1.97 
Ethyl acetate 6.02 Petroleum ether 1.90 
Dichloromethane 9.08 Petroleum ether 1.90 
Toluene 2.38 Petroleum ether 1.90 
Table 4. Common solvent-antisolvent pairs. (Adapted, with permission of the author, from 
Skonieczny, 2009.) 
2.2 Novel strategies and new trends in solvent-based crystallization 
One of the biggest challenges for pharmaceutical researchers is finding all the solid-state 
forms of an API that can exist at ambient conditions. There is no single method for 
producing all conceivable forms and a particular polymorph may go undetected for many 
years. Scientists are continually searching for novel ways of uncovering hidden solid-states. 
A few of these methods are briefly discussed below. 
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2.2.1 Laser-induced crystallization 
Non-photochemical laser-induced nucleation (NPLIN) is a crystallization technique that can 
affect both nucleation rate and the crystal form produced. Laser pulses act predominantly 
on pre-existing molecular clusters by assisting in the organization of pre-nucleating clusters 
and embryos into nuclei (Figure 2), leading to dramatically increased nucleation rates for 
supersaturated solutions. It is believed that the plane-polarized light aligns the pre-
nucleating clusters and thereby reduces the entropic barrier to the free energy of activation 
for critical nucleus formation (Banga et al., 2004; Garetz et al., 1996; Rodríguez-Spong et al., 
2004; Zaccaro et al., 2001). This method has not yet been applied to pharmaceuticals, but it 
should produce similar results as for other organic substances.  
2.2.2 Capillary crystallization 
In order to access metastable forms of an API, high levels of supersaturation are often 
required. Capillary tubes as recrystallization vessels are ideal for manipulating the 
metastable zone width through slow evaporation and because the small volumes of solution 
isolate heterogeneous nucleants, and reduce turbulence and convection. This technique 
offers the additional advantage that the crystals need not be removed from the capillary 
tube prior to characterization by single crystal- or powder X-ray diffraction (Banga et al., 
2004; Rodríguez-Spong et al., 2004). 
2.2.3 Sonocrystallization 
This technique utilizes ultrasound to increase nucleation rate, but it is also an effective 
means of crystal size reduction that eliminates many of the disadvantages associated with 
mechanical size reduction. Sonic waves give rise to a phenomenon called cavitation – the 
formation of bubbles that decrease in size until a critical size is reached, leading to collapse 
and the formation of cavities. Cavitation provides energy that accelerates the nucleation 
process (Banga et al., 2004; Kim et al, 2003). 
3. Non-solvent based recrystallization 
Much emphasis has been placed on the importance of solvent based recrystallization in the 
production of different solid-state forms of APIs, but non-solvent based recrystallization is 
equally important to industry and researchers alike. Recrystallization through solid-state 
transitions affects not only the production of APIs, but also the stability of the final product. 
Additionally, physical vapor deposition (PVD) recrystallization offers yet more 
opportunities for the preparation of polymorphs. 
3.1 Recrystallization through solid-state transitions 
Polymorphs may be obtained through solid-state transition by recrystallization of 
metastable polymorphs and amorphous forms, or through desolvation of solvates 
(including hydrates). No solid-state transition will take place unless it is thermodynamically 
favored and solids will always tend to transform to their lowest energy state – the most 
stable form. Stability is of major concern where APIs are concerned, but it is also true that 
stable forms are less soluble than their metastable counterparts and solubility of an API 
 
Recrystallization of Active Pharmaceutical Ingredients 195 
often affects its bioavailability, and therefore also its efficacy (Lipinsky et al., 1997). This 
necessitates a compromise between stability and solubility: we search for a metastable form 
with improved solubility that is still relatively stable enough to withstand the rigors of 
pharmaceutical processing and will yield a product with acceptable shelf-life. 
3.1.1 Transformation of polymorphs 
Polymorphism, occurring in a single-component crystalline molecular solid, may display 
monotropism or enantiotropism or both (Figure 8). In a monotropic system (A and C, B and 
C), only one polymorph is stable below the melting point and a phase change from the 
metastable form (A and B) to the stable form (C) is irreversible. For enantiotropic systems (A 
and B), a reversible phase transition is observed at a definite transition temperature (Tt,A-B), 
where the free energy curves intersect before the melting point (Tm). At temperatures and 
pressures below Tt,A-B form A will be stable (lower free energy and solubility), whilst in the 
temperature and pressure range between Tt,A-B and Tm,B form B is more stable. Polymorphs 
in an enantiotropic system are referred to as enantiotropes and those in a monotropic system 
are monotropes (Bernstein 2002; Grant 1999). 
 
Fig. 8. Gibbs free energy curves for a hypothetical single-component system that exhibits 
crystalline and amorphous phase transitions. Monotropic systems (A and C, B and C), 
enantiotropic system (A and B) with a transition temperature Tt, and an amorphous and 
super-cooled liquid with a glass transition temperature Tg. Melting points, Tm, for the 
crystalline phases are shown at the intersection of curves for the crystalline and liquid states. 
(Adapted, with permission of the authors, from Shalaev & Zografi, 2002.) 
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3.1.1.1 Effects of pharmaceutical processing 
Unintentional solid-state conversion of polymorphs sometimes occurs upon exposure to the 
energetics of pharmaceutical processing and a variety of phase conversions are possible 
when APIs are exposed to milling, wet granulation, oven drying, and compaction (Brittain 
& Fiese, 1999): 
Grinding or milling is often the last step in the production of bulk APIs and it is performed 
to reduce particle size and improve particle size homogeneity. Milling can impart a 
significant amount of energy on a solid and could potentially lead to a full or partial 
polymorphic conversion or generation of an amorphous substance (or at least a degree of 
amorphous content). Amorphous forms, being metastable, can in turn reconvert to a 
crystalline state which may differ from the original product. 
Wet granulation, used to improve powder flow and blend homogeneity, is a step that often 
precedes the production of tablets. During this process, the API is exposed to a solvent 
(water or an organic solvent with low toxicity, like ethanol) and is once more prone to 
undergoing solvent-mediated transformations. Exposure to humidity can create similar 
conditions which could lead to a hydrate being formed. 
Drying of APIs is typically achieved with heat and moving air. The possible ramifications of 
temperature change on polymorph stability have been discussed in the previous section. 
Drying conditions need to be carefully controlled to avoid possible transformations. 
Although not generally a common occurrence, compaction (during tablet manufacturing) 
can potentially cause metastable polymorphs to convert to the stable form. This can be 
attributed to the energy applied to bring about compaction. The extent of transformation is 
dependent on the zone of the tablet, the pressure applied, the compression temperature and 
the particle size of the API powder. 
3.1.1.2 High-pressure polymorphic transitions 
Solid-state pressure-induced structural changes in molecular crystals can cause 
polymorphic transitions (Boldyreva, 2003). However, unlike with high-pressure solvent 
recrystallization (please refer to section 2.1.5) which is experimentally and mechanistically 
similar, the conversion tends to be only partial and the data are poor. It is thought that 
even though the application of high pressure to larger organic molecules may 
thermodynamically favor the adoption of a new polymorphic form, the solid-state has a 
substantial kinetic barrier to overcome before the molecules are mobile enough to 
rearrange (Fabbiani et al., 2004). 
3.1.2 Desolvation of hydrates and solvates 
With the exception of hydrates that are often used in pharmaceutical dosage forms, most 
solvates are the penultimate solid form in the production of APIs (Byrn et al., 1999). Solvates 
may be desolvated by removing the recrystallization solvent and exposing the crystals to air 
at ambient temperature, leading to a decrease in vapor pressure of the solvent. If a solvate is 
stable under these conditions, it may be dried under vacuum or in an oven at mild 
temperatures. 
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Desolvation of a solvate generally results in one of the following forms (Byrn et al., 1999): 
 An unsolvated polymorph with a crystal structure different to that of the solvate. 
 An unsolvated polymorph with a crystal structure that is the same as that of the solvate. 
 An amorphous material that may or may not recrystallize. 
Sometimes, a polymorphic transition may mimic the first of these scenarios. Nevirapine’s 
metastable Form IV is isostructural to a series of solvates prepared from primary alcohols 
(Stieger et al., 2010b) except that its structure contains no solvent molecules. When removed 
from its recrystallization medium, Form IV will spontaneously and rapidly convert to the 
stable Form I in exactly the same way as the aforementioned solvates (Stieger et al., 2009). 
3.1.3 Crystallization from amorphous phases 
Amorphous pharmaceutical solids may be prepared by common pharmaceutical processes 
including melt quenching, freeze- and spray-drying, milling, wet granulation and 
desolvation of solvates (Yu, 2001). Glasses are most often produced from a melt of an API. If 
crystallization does not occur on cooling the melt below the melting point (Tm) of the 
crystalline phase, a supercooled liquid is obtained. Further cooling induces a change to a 
glassy state at the glass transition temperature (Tg), accompanied by a dramatic decrease in 
molecular mobility and heat capacity. In contrast to melting point, the glass transition 
temperature of a compound can fluctuate with operating conditions (including the rate of 
cooling/heating) and as a function of the history of the sample. This indicates that the glass 
transition is a thermal event affected by kinetic factors (Petit & Coquerel, 2006). 
An amorphous or glass form is often an intermediate in the production of crystalline APIs 
and such processes can be useful for overcoming specific kinds of activation energies. 
Thermodynamically, amorphous solids are out-of-equilibrium states that contain an excess 
of stored energy, with reference to the crystalline phases (Figure 9), making them unstable 
by definition. The excess energy can be released either completely through crystallization or 
partially by means of irreversible relaxation processes (Petit & Coquerel, 2006). 
Crystallization from amorphous solids, as for any crystallization, involves successive 
nucleation and growth steps. The crystallization rate may be affected by numerous, possibly 
interdependent, parameters notably including temperature and plasticizers (of which water 
is one). When the temperature of a supercooled liquid decreases from the melting point to 
the glass transition temperature, the nucleation rate increases exponentially whereas 
molecular mobility required for growth decreases exponentially. A maximum crystallization 
rate therefore occurs between preferred temperatures of nucleation and growth. Cooling 
rate also affects nucleation, with slow cooling allowing the maintenance of a steady-state 
nucleation rate. Rapid cooling, on the other hand, prevents full development of nucleation 
and thereby facilitates glass formation (Petit & Coquerel, 2006; Yu, 2001). 
Amorphous solids offer certain pharmaceutical advantages over their crystalline 
counterparts. They are more soluble, have higher dissolution rates, and in some cases they 
may even have better compression characteristics than corresponding crystals. Therefore, 
we may not necessarily want amorphous APIs to recrystallize. Some pharmaceuticals have a 
natural tendency to exist as amorphous solids, while others require deliberate prevention of 
recrystallization to enter, and remain in, the amorphous state. Contemporary research into 
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the stabilization of amorphous pharmaceuticals focuses on three key areas: (1) the use of 
additives for the stabilization of labile substances (e.g. proteins and peptides) during 
processing and storage; (2) prevention of crystallization of excipients that must remain 
amorphous to perform their intended functions; and (3) determining the appropriate storage 
conditions for optimal stability of amorphous materials (Yu, 2001). 
 
Fig. 9. Schematic representation of enthalpy or volume variations as a function of 
temperature for condensed materials. (Adapted, with permission of John Wiley and Sons, 
from Petit & Coquerel, 2006.) 
3.2 Recrystallization through Physical Vapor Deposition 
Physical vapor deposition (PVD) is an atomistic deposition process in which material is 
vaporized from a solid or liquid source in the form of atoms or molecules and transported in 
the form of vapor through a low pressure environment to the substrate where it condenses 
(Mattox, 1998). During the PVD process, molecules unpack from the original crystal lattice 
and then recrystallize in the new lattice (Byrn et al., 1999). 
The research into pharmaceutical applications of PVD has, to date, largely been limited to 
the production of amorphous phases – particularly ones with enhanced stability. Although 
we have long known that sublimation may be used for the production of polymorphs, 
comparatively few papers have been published on recrystallization via PVD. This is 
surprising when one considers that approximately two-thirds of organic compounds 
sublime (Guillory, 1999) and most commercially available APIs are crystalline. 
Studies on the sublimation-based recrystallization of the following APIs and organic 
compounds have been published: anthranilic acid (Carter & Ward, 1994); 9,10-
anthraquinone-2-carboxilic acid (Tsai et al., 1993); 1,1-bis(4-hydroxyphenyl)cyclohexane 
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(Sarma et al., 2006); caffeine (Griesser et al., 1999; Carlton, 2011); carbamazepine (Griesser et 
al., 1999; Zeitler et al., 2007); 1,3-dimethyluracil (Sakiyama & Imamura, 1989); ibuprofen 
(Perlovich et al., 2004;); malonamide (Sakiyama & Imamura, 1989); nevirapine (Figure 10) 
(Stieger & Liebenberg, 2009); stanozolol (Karpinska et al., 2011); and theophylline (Fokkens 
et al., 1983; Griesser et al., 1999). 
 
Fig. 10. Micro-spherical aggregates of nano-crystalline nevirapine prepared by PVD (A), the 
individual crystallites of which could be obtained through light grinding (B). 
 
Fig. 11. Pressure-temperature diagram of a one-component crystalline solid for which only 
one solid phase exists. (Adapted, with permission of Dover Publications, from Ricci, 1966.) 
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Figure 11 demonstrates how transformations mediated by the vapor phase are highly 
dependent on vapor pressure and therefore also on temperature (Byrn et al., 1999). Vapor of 
an API can be generated by its liquid phase once melted (evaporation) or by its solid phase 
(sublimation). The vast majority of pharmaceutical actives are organic compounds and, as 
such, they are sensitive to heat degradation. It is well-known that many APIs degrade when 
melted. It follows that pharmaceutical PVD processes should ideally operate at low pressure 
and temperature to obtain vapor through sublimation, using compounds with sufficient 
thermal stability. 
Figure 12 illustrates how it is possible to obtain different enantiotropic polymorphs through 
vapor deposition. At a pressure sufficiently low for sublimation to take place the solid API 
becomes a vapor, at which point it is no longer Solid A or B because polymorphism is a 
solid-state phenomenon. The temperature at which the vapor phase recrystallizes 
determines which polymorph is obtained (provided the pressure is sufficiently low). It can 
generally be assumed that unstable/metastable polymorphs (in this example, Solid A) will 
form preferentially at lower temperatures and stable polymorphs (Solid B) can be expected 
at higher temperatures (Guillory, 1999). This is why the temperature, and distance from the 
solid, of the collection surface is so important in PVD systems. 
 
Fig. 12. Pressure-temperature diagram of a one-component crystalline solid with 
enantiotropic behavior. (Adapted, with permission of John Wiley and Sons, from Lohani & 
Grant, 2006.) 
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It has, incidentally, been found that recrystallization from the vapor phase can also be 
affected or controlled by the nature of the substrate (Carter & Ward, 1994) as has been 
shown for solvent recrystallization (Rodríguez-Spong et al., 2004). 
4. Conclusion  
Polymorphs of active pharmaceutical ingredients can be obtained though recrystallization 
processes based on solvents, solid-state transitions and vapor deposition. When the possible 
number of experimental variations on each of these is considered, it is easy to become 
overwhelmed by the task of comprehensive polymorph screening. Indeed, it is no wonder 
that some polymorphs go undetected for decades or longer. Various semi-automated and 
high-throughput methods have been developed to assist in this daunting task. The efforts of 
researchers laboring towards automation are, however “subverted” by colleagues who 
continually find novel ways of accessing hidden polymorphs!  There is, to date, no single 
method that can identify all possible solid forms of an API. 
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